ANZMUSC is proud to announce one of its trials, the PRECISE (Pregabalin in Addition to Usual care for Sciatica) Trial was awarded the 2018 Finalist for ‘Trial of the Year’ sponsored by the Australian Clinical Trials Alliance (ACTA). This award is in “recognition of outstanding achievement in an investigator-initiated clinical trial”. PRECISE was also awarded finalist in ACTA STInG (Statistics in Trials Interest Group) Excellence in Trial Statistics Award.
The award was presented to A/Prof Christine Lin (Principal Research Fellow, Musculoskeletal Health Sydney, School of Public Health, The University of Sydney) and Prof Jane Latimer (Deputy Director, Musculoskeletal Health Sydney, School of Public Health, The University of Sydney) by the Hon. Greg Hunt MP, Federal Minister for Health at the Clinical Trials 2018 National Tribute & Awards Ceremony held at the Royal Melbourne Hospital on Wednesday 16th of May.
The PRECISE trial was the first trial to rigorously examine the efficacy and safety of pregabalin in sciatica, and provided unequivocal evidence against its use for this condition. The results ruled out any clinically worthwhile treatment benefits and showed that taking pregabalin is associated with an increased risk of adverse events compared to placebo in patients with moderate to severe sciatica. The results were published in the New England Journal of Medicine.
PRECISE was led by a team of investigators who are ANZMUSC members based at The University of Sydney and The George Institute for Global Health.
We congratulate the PRECISE study team on their success, and for being the first ANZMUSC trial to receive this award.